Ocular Therapeutix, Inc. has announced Baxter Ventures has acquired a minority equity stake in the company.

Ocular Therapeutix, a privately held company based in Bedford, Mass., develops and commercializes ophthalmic therapeutic products using proprietary hydrogel technology.

Baxter Ventures is a PE fund established by Baxter International Inc. in 2011 to invest up to $200 million in equity in early-stage companies developing therapies that complement Baxter’s existing portfolio.

This round of funding, which also involved Ascension Health Ventures, will be used to support U.S. commercial launch of Ocular Therapeutix’s ReSure Sealant following FDA approval of the device.